Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00275015
Recruitment Status : Completed
First Posted : January 11, 2006
Last Update Posted : May 10, 2018
Information provided by:
German CLL Study Group

Brief Summary:

RATIONALE: Giving chemotherapy before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy or radiation therapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy.

PURPOSE: This phase II trial is studying how well giving cyclophosphamide together with total-body irradiation works in treating patients who are undergoing an peripheral stem cell transplant for chronic lymphocytic leukemia.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Biological: filgrastim Drug: carmustine Drug: cyclophosphamide Drug: cytarabine Drug: dexamethasone Drug: etoposide Drug: fludarabine phosphate Drug: melphalan Procedure: bone marrow ablation with stem cell support Procedure: peripheral blood stem cell transplantation Radiation: radiation therapy Phase 2

Detailed Description:



  • Determine the safety and feasibility of autologous peripheral blood stem cell transplantation in patients with chronic lymphocytic leukemia treated with cyclophosphamide and total-body irradiation.


  • Determine the safety, feasibility, and efficacy of combination therapy comprising dexamethasone, carmustine, cytarabine, etoposide, and melphalan (Dexa-BEAM) and filgrastim (G-CSF) mobilization in patients treated with this regimen.
  • Determine the efficacy of ex-vivo graft purging in patients treated with this regimen.
  • Determine the incidence of complete clinical and molecular remissions in patients treated with this regimen.
  • Determine the progression-free survival of patients treated with this regimen.

OUTLINE: This is a multicenter, open-label, nonrandomized study.

  • Cytoreductive treatment: Patients undergo 2-4 courses of cytoreductive treatment, preferably following the fludarabine and cyclophosphamide (FC) protocol.
  • Stem cell mobilization: Patients achieving a complete remission (CR) or partial remission (PR) and stable blood counts undergo stem cell mobilization comprising dexamethasone, carmustine, cytarabine, etoposide, melphalan (Dexa-BEAM), and filgrastim (G-CSF). Patients with an adequate number of mobilized cells undergo stem cell collection. Patients with CR or very good PR proceed to myeloablative therapy.
  • Myeloablative therapy: Patients undergo total-body irradiation on day -4 and receive cyclophosphamide IV on days -4 and -3.
  • Autologous peripheral blood stem cell transplantation (PBSCT): Patients undergo autologous PBSCT on day 0.

After completion of study, patients are followed periodically.

PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 169 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pivotal Study for High Dose Therapy and Autologous Stem Cell Transplantation in Early Stages of CLL
Study Start Date : January 1998
Actual Study Completion Date : April 2012

Arm Intervention/treatment
Experimental: High dose therapy + autologous PBSCT
  1. Cytoreductive treatment: (preferentially) FC (2-4 cycles)
  2. Mobilization: Dexa-BEAM + G-CSF (1-2 cycles)
  3. Myeloablation:

    fractionated TBI (e.g. 6x2Gy) + Cyclophosphamide (2 x 60 mg/kg; d -4 to -3)

  4. autologous peripheral blood stem cell transplantation (PBSCT) (d 0)
Biological: filgrastim
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

Primary Outcome Measures :
  1. Safety of autologous peripheral stem cell transplantation (PBSCT) as measured by a treatment-related mortality of < 5% at 12 months following transplant
  2. Feasibility of PBSCT as measured by > 50% of included patients proceeding to transplant

Secondary Outcome Measures :
  1. Safety of mobilization comprising dexamethasone, carmustine, cytarabine, etoposide, and melphalan (Dexa-BEAM) as measured by a treatment-related mortality of < 5% before transplant phase
  2. Efficacy of Dexa-BEAM mobilization as measured by the amount of CD34+ cells > 4x10e6/kg at harvest
  3. Complete clinical remissions by NIH criteria at 3 months following transplant
  4. Molecular remissions by CDR3 PCR at 3 months following transplant
  5. Progression-free survival by NIH criteria at 5 years from study entry

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Patients with chronic lymphocytic leukemia, meeting 1 of the following criteria:

    • Binet stage B or C disease
    • Binet stage A disease and at high risk for disease progression, defined as the following:

      • Non-nodular marrow infiltration or lymphocyte doubling time < 12 months
      • Thymidine kinase > 7.0 U/L or ß-2-microglobulin > 3.5 mg/L
  • Polymerase chain reaction-amplifiable clonal CDRIII rearrangement of the IgV_H


  • ECOG performance status 0-1
  • No concurrent disease resulting in major organ dysfunction


  • No prior combination therapy comprising melphalan, dexamethasone, carmustine, cytarabine, and etoposide (DEXA-Beam)
  • No more than 1 prior chemotherapy regimen
  • No prior chemotherapy regimen longer than 6 months in duration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00275015

  Hide Study Locations
Vienna, Austria, A-1140
Allg. Krankenhaus der Stadt Wien Universitaets-Kinderklinik
Wien, Austria, A-1090
Humaine - Clinic
Bad Saarow, Germany, D-15526
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin
Berlin, Germany, D-12200
Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch
Berlin, Germany, D-13122
Universitaetsklinikum Bonn
Bonn, Germany, D-53105
Praxis Dres. F.& G. Doering
Bremen, Germany, D-28205
Universitatsklinikum Carl Gustav Carus
Dresden, Germany, D-01307
Universitaetsklinikum Duesseldorf
Duesseldorf, Germany, D-40225
Michael Schaefers und Partner
Duisburg, Germany, D-47051
Onkologische Schwerpunkt Praxis
Erlangen, Germany, D-91052
Universitaetsklinikum Essen
Essen, Germany, D-45122
Malteser Krankenhaus
Flensburg, Germany, D-24939
Gemeinschaftspraxis Fuer Innere Medizin, Hematologie Und Onkologie
Giessen, Germany, D-35392
Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet
Greifswald, Germany, D-17487
Universitätsklinikum Göttingen
Göttingen, Germany, D-37075
Asklepios Klinik St. Georg
Hamburg, Germany, D-20099
St. Marien-Hospital Hamm - Klinik Knappenstrasse
Hamm, Germany, D-59071
Krankenhaus Siloah - Medizinische Klinik II
Hannover, Germany, D-30449
Medizinische Hochschule Hannover
Hannover, Germany, D-30625
Universitaets-Kinderklinik Heidelberg
Heidelberg, Germany, D-69120
Universitatsklinikum Heidelberg
Heidelberg, Germany, D-69120
Universitaetsklinikum des Saarlandes
Homburg, Germany, D-66421
Klinikum der Friedrich-Schiller Universitaet Jena
Jena, Germany, D-07740
Westpfalz-Klinikum GmbH
Kaiserslautern, Germany, D-67653
Gemeinschaftspraxis fuer Haematologie, Onkologie und Infektiologie
Karlsruhe, Germany, D-76135
Internistische Gemeinschaftspraxis - Kassel
Kassel, Germany, D-34117
Staedtisches Krankenhaus Kiel
Kiel, Germany, D-23116
University Leipzig Clinic of Internal Medicine
Leipzig, Germany, D-04103
Universitaets - Kinderklinik - Luebeck
Lubeck, Germany, D-23538
Sana Kliniken Luebeck
Luebeck, Germany, D-23560
Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg
Magdeburg, Germany, D-39120
Universitatsklinik Mainz
Mainz, Germany, D-55101
Krankenhaus Maria Hilf GmbH
Moenchengladbach, Germany, D-41063
University of Muenster
Muenster, Germany, D-48129
Klinikum der Universitaet Muenchen - Innenstadt Campus
Munich, Germany, D-80331
Krankenhaus Muenchen Schwabing
Munich, Germany, D-80804
Klinikum der Universitaet Muenchen - Grosshadern Campus
Munich, Germany, D-81377
Staedtisches Krankenhaus Muenchen - Harlaching
Munich, Germany, D-81545
Internistische Praxis - Neuss
Neuss, Germany, D-41460
Praxis fuer Haematologie und Interne Onkologie
Norderstedt, Germany, D-22844
Klinikum Nuernberg - Klinikum Nord
Nuernberg, Germany, D-90419
Internistische Gemeinschaftspraxis - Oldenburg
Oldenburg, Germany, D-26121
Klinikum Oldenburg
Oldenburg, Germany, D-26133
Klinikum Ernst Von Bergmann
Potsdam, Germany, D-14467
Klinik und Poliklinik fuer Innere Medizin - Universitaet Rostock
Rostock, Germany, D-18057
Diakonie Klinikum Stuttgart
Stuttgart, Germany, D-70176
Buergerhospital Stuttgart
Stuttgart, Germany, D-70191
Internistische Praxis - Trier
Trier, Germany, D-54290
Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm
Ulm, Germany, D-89081
Deutsche Klinik fuer Diagnostik
Wiesbaden, Germany, D-65191
Hamatologisch - Onkologische Praxis Wurzburg
Wurzburg, Germany, D-97070
University Wurzburg
Wurzburg, Germany, D-97070
Sponsors and Collaborators
German CLL Study Group
Study Chair: Peter Dreger Universitaets-Kinderklinik Heidelberg

Additional Information:
Publications of Results: Identifier: NCT00275015     History of Changes
Other Study ID Numbers: CLL3
First Posted: January 11, 2006    Key Record Dates
Last Update Posted: May 10, 2018
Last Verified: May 2018

Keywords provided by German CLL Study Group:
stage 0 chronic lymphocytic leukemia
stage I chronic lymphocytic leukemia
stage II chronic lymphocytic leukemia
stage III chronic lymphocytic leukemia
stage IV chronic lymphocytic leukemia
refractory chronic lymphocytic leukemia

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Fludarabine phosphate
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Immunosuppressive Agents